NAGE Niagen Bioscience Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: NAGE

Price (delayed)

$3

Market cap

$237.38M

P/E Ratio

15

Dividend/share

N/A

EPS

$0.2

Enterprise value

$172.97M

?
Relative Growth: Rel. Growth: 27
Relative Strength: Rel. Strength: 8
Relative Valuation: Rel. Valuation: 69
Relative Profitability: Rel. Profitability: 75

Niagen Bioscience is a global bioscience company dedicated to healthy aging. The Niagen Bioscience team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme ...

Highlights
NAGE's quick ratio has surged by 59% year-on-year and by 43% since the previous quarter
The stock's price to earnings (P/E) is 37% less than its last 4 quarters average of 24.5
The company's EPS fell by 17% QoQ and by 13% YoY
The company's net income fell by 14% QoQ and by 10% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.chromadex.com
Peers: NAII EXEL

Key stats

What are the main financial stats of NAGE

NAGE stock price

How has the Niagen Bioscience stock price performed over time
Intraday
-2.91%
1 week
0%
1 month
-6.54%
1 year
-70.59%
YTD
-52.83%
QTD
-5.96%

Financial performance

How have Niagen Bioscience's revenue and profit performed over time
Revenue
$129.08M
Gross profit
$82.92M
Operating income
$10.6M
Net income
$15.99M
Gross margin
64.2%
Net margin
12.4%
NAGE's operating margin is down by 43% year-on-year and by 18% since the previous quarter
Niagen Bioscience's operating income has decreased by 36% YoY and by 19% QoQ
Niagen Bioscience's net margin has decreased by 18% YoY and by 13% from the previous quarter
The company's net income fell by 14% QoQ and by 10% YoY

Price vs fundamentals

How does NAGE's price correlate with its fundamentals

Growth

What is Niagen Bioscience's growth rate over time

Valuation

What is Niagen Bioscience stock price valuation
NAGE P/E details
P/E
15
P/B
2.9
P/S
1.84
EV/EBIT
10.16
EV/EBITDA
9.26
EV/Sales
1.34
The stock's price to earnings (P/E) is 37% less than its last 4 quarters average of 24.5
The company's EPS fell by 17% QoQ and by 13% YoY
NAGE's price to book (P/B) is 58% lower than its 5-year quarterly average of 7.1 and 51% lower than its last 4 quarters average of 6.1
The equity rose by 29% year-on-year
NAGE's price to sales (P/S) is 47% lower than its last 4 quarters average of 3.6 and 41% lower than its 5-year quarterly average of 3.2
The revenue has grown by 11% YoY

Efficiency

How efficient is Niagen Bioscience business performance
NAGE's return on invested capital has dropped by 56% year-on-year and by 25% since the previous quarter
The company's return on equity fell by 42% YoY and by 19% QoQ
Niagen Bioscience's return on assets has decreased by 37% YoY and by 18% QoQ
The company's return on sales fell by 16% YoY and by 13% QoQ

Dividends

What is NAGE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NAGE.

Financial health

How did Niagen Bioscience financials performed over time
The current ratio has surged by 68% year-on-year and by 41% since the previous quarter
NAGE's quick ratio has surged by 59% year-on-year and by 43% since the previous quarter
Niagen Bioscience's debt is 97% less than its equity
NAGE's debt to equity is down by 40% year-on-year
The equity rose by 29% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.